Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected price increase of over 15% in the next 6-12 months [4]. Core Insights - The company reported a revenue of 1.852 billion RMB and a net loss of 2.595 billion RMB for 2025, significantly impacted by a fair value change of financial liabilities amounting to 2.206 billion RMB [2]. - The core product HER2 ADC DB-1303 has completed Phase III clinical trials for breast cancer and submitted a Biologics License Application (BLA) in China, with global trials for HR+HER2 low breast cancer also progressing [2][3]. - The company is actively developing a pipeline of next-generation ADC therapies, with several products in various stages of clinical trials, including DB-2304 for lupus and DB-1418 for lung cancer [3]. Financial Forecasts - Revenue projections for 2026 and 2027 are set at 1.952 billion RMB and 2.407 billion RMB, respectively, with an additional forecast of 3.085 billion RMB for 2028 [4]. - Expected net losses for 2026 and 2027 are projected at 377 million RMB and 406 million RMB, with a further forecast of 333 million RMB for 2028 [4]. - The company is expected to see a revenue growth rate of 5.42% in 2026 and 23.29% in 2027, with a significant increase in 2028 [9].
映恩生物-B（09606）：港股公司点评：临床管线持续推进，迈向收获期